Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.

Autor: Nakahara Y; Department of Respiratory Medicine, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.; Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan., Kouro T; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan., Motoyama S; Department of Comprehensive Cancer Control, Akita University Graduate School of Medicine, Akita, Japan.; Division of Esophageal Surgery, Akita University Hospital, Akita, Japan.; Department of Gastroenterological Surgery, Japanese Red Cross Akita Hospital, Akita, Japan., Miura M; Department of Pharmacy, Akita University Hospital, Akita, Japan., Fujita K; Department of Pharmacy, Akita University Hospital, Akita, Japan., Igarashi Y; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan., Higashijima N; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan., Matsuo N; Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan., Himuro H; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan., Wei F; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan., Horaguchi S; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.; Department of Pediatric Surgery, Nihon University School of Medicine, Tokyo, Japan., Tsuji K; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan., Mano Y; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan., Komahashi M; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.; Department of Pediatric Surgery, Nihon University School of Medicine, Tokyo, Japan., Saito H; Department of Respiratory Medicine, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan., Azuma K; Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan., Sasada T; Cancer Vaccine and Immunotherapy Center, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.; Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.

Publikováno v: Frontiers in cell and developmental biology [Front Cell Dev Biol] 2024 Jan 16; Vol. 11, pp. 1324898. Date of Electronic Publication: 2024 Jan 16 (Print Publication: 2023).